Qiagen NV (QGEN)

34.57
0.15 0.43
NASDAQ : Services
Prev Close 34.72
Open 34.76
Day Low/High 34.54 / 34.88
52 Wk Low/High 19.94 / 28.53
Volume 810.47K
Avg Volume 803.60K
Exchange NASDAQ
Shares Outstanding 227.66M
Market Cap 7.95B
EPS 0.30
P/E Ratio 102.74
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EFII, ENBL, NNBR, PHI, QGEN, SYX, TIER, WEX, WILC Downgrades: ADES, AEGN, ARES, CVLT, ECOM, PSX, WES Initiations: WATT Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Receives U.S. FDA Approval For Cytomegalovirus (CMV) Testing On Automated QIAsymphony Platform

High-throughput application of artus CMV QS-RGQ MDx Kit on QIAsymphony streamlines critical and frequently performed viral infection test for transplant patients

Bristol-Myers Squibb And QIAGEN Sign Agreement For Use Of NGS Technology To Develop Gene Expression Profiles For Immuno-Oncology Therapies

Bristol-Myers Squibb Company (NYSE:BMY) and QIAGEN (NASDAQ:QGEN; Frankfurt Prime Standard:QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression...

QIAGEN Expands Biomarker Content Portfolio To Support Greater Use Of Molecular Diagnostics For Immuno-oncology Therapies

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN's NGS panels

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

New Research Suggests Potential For Additional Clinical Utility Of QIAGEN's QuantiFERON-TB Gold Plus

Findings indicate increased specificity in low-risk populations and potential for monitoring tuberculosis treatment

QIAGEN Expands Liquid Biopsy Pipeline With AR-V7 Test In Prostate Cancer

Exclusive license to RNA biomarker from The Johns Hopkins University clears path to commercialization

QIAGEN Joins CANCER-ID Consortium For Liquid Biopsy Workflows

Public-private partnership aims to standardize and clinically validate blood-based biomarkers

QIAGEN Launches First FDA-cleared JAK2 Test For Certain Type Of Leukemia

New biomarker test - the fifth QIAGEN oncology test with FDA clearance in the U.S. - designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Cytokinetics, Achillion and Qiagen were among the biotech stock movers in premarket trading on Thursday.

QIAGEN's QuantiFERON-TB Test Wins Tender For Testing Of Republic Of Korea Armed Forces Recruits

QIAGEN's QuantiFERON-TB Test Wins Tender For Testing Of Republic Of Korea Armed Forces Recruits

Selected for screening of 340,000 recruits in 2017 as part of national TB control strategy

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

Adjustment of conversion ratio under 0.375% Senior Unsecured Convertible Notes due 2019 due to reduction in number of shares outstanding and direct capital repayment to shareholders

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

Adjustment of conversion ratio under 0.375% Senior Unsecured Convertible Notes due 2019 due to reduction in number of shares outstanding and direct capital repayment to shareholders

QIAGEN Announces Details For Completion Of Approximately $250 Million Synthetic Share Repurchase

QIAGEN Announces Details For Completion Of Approximately $250 Million Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment set for completion in January 2017

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

Powerful multi-omics data management solution and highly curated 'omics' data sets complement QIAGEN's industry-leading interpretation solutions

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

Launch of new QIAact gene panels and customized panels service complemented by performance upgrades that further differentiate first Sample to Insight NGS sequencing solution

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

U.S. submission builds on 2016 launch of fourth-generation test in more than 60 countries and already used in more than 600,000 people to date